Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | TG01 |
Trade Name | |
Synonyms | TG-01|TG 01 |
Drug Descriptions |
TG01 is a peptide-based cancer vaccine consisting of 7 RAS peptides specific to KRAS G12 and G13 mutations, which potentially induces RAS-specific antitumor immune response (PMID: 32063605). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C200465 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Balstilimab + QS21 + TG01 | Balstilimab QS21 TG01 | 0 | 1 |
Daratumumab + Nivolumab + QS21 + TG01 | Daratumumab Nivolumab QS21 TG01 | 0 | 1 |
Daratumumab + Nivolumab + TG01 | Daratumumab Nivolumab TG01 | 0 | 0 |
Gemcitabine + Sargramostim + TG01 | Gemcitabine Sargramostim TG01 | 0 | 0 |
QS21 + TG01 | QS21 TG01 | 0 | 2 |
TG01 | TG01 | 0 | 0 |